top of page


Eli Lilly agrees to acquire Calytrix Bio for up to $1.5 billion to expand rare blood cancer pipeline
Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion, adding a preclinical antibody programme targeting mutant calreticulin in rare myeloproliferative blood disorders.

nuaxia
1 hour ago2 min read


FDA approves Besremi for adults with essential thrombocythemia
The FDA has approved Besremi for adults with essential thrombocythemia, extending ropeginterferon alfa-2b-njft into a second myeloproliferative neoplasm indication in the United States.

nuaxia
Sep 12 min read


FDA approves Mimrylo for adults with polycythemia vera
Mimrylo is the first FDA-approved polycythemia vera treatment designed to mimic hepcidin, targeting the iron availability that drives excessive red blood cell production.

nuaxia
Sep 12 min read
bottom of page